Wang R, Nishioka K, Tanno Y
Research Unit of Clinical Pharmacology, Chinese PLA General Hospital.
Zhonghua Nei Ke Za Zhi. 1994 Feb;33(2):95-8.
The morbidity of the infections caused by methicillin resistant staphylococcus aureus increased in recent years. In order to know the resistance of MRSA to antimicrobial agents, the minimal inhibitory concentrations (MICs) of antimicrobial agents against S. Aureus isolated from inpatients were measured. The presence of beta-lactamase in and the types of coagulase of the strains tested were determined as well. The results showed that MRSA accounted for 50.7% of the strains tested, the incidence of MRSA producing beta-lactamase was 85.1% and the coagulase of MRSA was all of type II. MRSA showed resistance to most of the lactam antibiotics and some of the aminoglycosides. Vancomycin and arbikacin had the highest activity against MRSA; other effective antibiotics were in the following order: amikacin, minocycline, tosulfloxacin and imipenem. It is suggested that serious infections caused by MRSA may be cured by using vancomycin, arbikacin or other antibiotics mentioned above.
近年来，耐甲氧西林金黄色葡萄球菌引起的感染发病率有所上升。为了解耐甲氧西林金黄色葡萄球菌（MRSA）对抗菌药物的耐药性，测定了抗菌药物对住院患者分离出的金黄色葡萄球菌的最低抑菌浓度（MIC）。同时还测定了受试菌株中β-内酰胺酶的存在情况以及凝固酶的类型。结果显示，MRSA占受试菌株的50.7%，产β-内酰胺酶的MRSA发生率为85.1%，且MRSA的凝固酶均为Ⅱ型。MRSA对大多数β-内酰胺类抗生素和一些氨基糖苷类抗生素耐药。万古霉素和阿贝卡星对MRSA的活性最高；其他有效的抗生素依次为阿米卡星、米诺环素、妥舒沙星和亚胺培南。建议使用万古霉素、阿贝卡星或上述其他抗生素治疗由MRSA引起的严重感染。
